Bausch Health Companies Inc (NYSE/TSX: BHC), a Canada-based multinational specialty pharmaceutical company, announced on Wednesday that it has received an additional new indication for DEXAVEN (dexamethasone phosphate) solution for injection, 4mg/ml, from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland.
The product is intended to treat COVID-19 in adult and adolescent patients over 12 years of age and older, weighing around 40kg and in need of oxygen therapy. It is a corticosteroid that decreases inflammation.
The United States Food and Drug Administration (FDA) has not granted approval to Dexamethasone-containing products in the United States for the treatment for COVID-19. The products are only to be used in accordance with their approved label and under the directions of the patient's doctor.
Bambusa Therapeutics names new CFO
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform
Vimgreen Pharmaceuticals receives IND clearance for VG081821 in China
Inimmune reports dosing of first patient in Phase 2 allergen challenge chamber trial of INI-2004
Gesynta Pharma doses first patient in vipoglanstat Phase 2 clinical proof-of-concept trial
Immunic granted European patent for vidofludimus calcium dosing regimens
Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment
Pfizer reports positive Phase 2 results for trispecific antibody in atopic dermatitis
Kelun-Biotech and Harbour BioMed receive China IND approval for atopic dermatitis therapy
Melodia Therapeutics reports award of US patent covering MLD-151
GSK to acquire 35Pharma for USD950m to strengthen cardiopulmonary pipeline
Gossamer Bio reports topline Phase 3 PROSERA results for seralutinib in PAH
Formosa Pharmaceuticals signs licensing deal with Arrotex for APP13007 in Australia and New Zealand
Merck and Mayo Clinic launch AI-driven drug discovery collaboration